We are live on ! Find out more
BMY icon

Bristol-Myers Squibb

1,523 hedge funds and large institutions have $63.3B invested in Bristol-Myers Squibb in 2016 Q3 according to their latest regulatory filings, with 110 funds opening new positions, 663 increasing their positions, 548 reducing their positions, and 147 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 663 | Existing positions reduced: 548

3.14% less ownership

Funds ownership: 73.94%70.8% (-3.1%)

3% less funds holding

Funds holding: 1,5771,523 (-54)

17% less call options, than puts

Call options by funds: $1.15B | Put options by funds: $1.38B

25% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 147

30% less capital invested

Capital invested by funds: $90.9B → $63.3B (-$27.6B)

55% less funds holding in top 10

Funds holding in top 10: 11049 (-61)

Holders
1,523
Holders Change
-54
Holders Change %
-3.42%
% of All Funds
40.62%
Holding in Top 10
49
Holding in Top 10 Change
-61
Holding in Top 10 Change %
-55.45%
% of All Funds
1.31%
New
110
Increased
663
Reduced
548
Closed
147
Calls
$1.15B
Puts
$1.38B
Net Calls
-$227M
Net Calls Change
-$366M
Name Holding Trade Value Shares
Change
Change in
Stake
TMAM
276
Tokio Marine Asset Management
Japan
$14.1M -$809K -12,593 -5%
SAM
277
Shell Asset Management
Netherlands
$14.1M -$2.07M -32,235 -11%
PA
278
Pinnacle Associates
New York
$13.9M +$94.7K +1,474 +0.6%
N
279
Natixis
France
$13.9M +$9.39M +146,252 +131%
V
280
Veritable
Delaware
$13.9M -$428K -6,667 -3%
CIBC World Market
281
CIBC World Market
Ontario, Canada
$13.9M +$7.85M +122,205 +91%
SAM
282
Silvercrest Asset Management
New York
$13.7M -$20.2K -314 -0.1%
ZDA
283
Zweig-DiMenna Associates
New York
$13.6M -$3.01M -46,850 -16%
Nordea Investment Management
284
Nordea Investment Management
Sweden
$13.6M -$298K -4,640 -2%
XK
285
Xact Kapitalforvaltning
Sweden
$13.5M +$16.1M +251,284 New
JMPWA
286
JP Morgan Private Wealth Advisors
California
$13.5M +$666K +10,365 +4%
RSCM
287
Rock Springs Capital Management
Maryland
$13.5M +$3.44M +53,500 +27%
ABC
288
Associated Banc-Corp
Wisconsin
$13.3M +$550K +8,569 +4%
CLOS
289
Compagnie Lombard Odier SCmA
Switzerland
$13.2M -$109K -1,700 -0.7%
Nomura Asset Management
290
Nomura Asset Management
Japan
$13M -$263K -4,102 -2%
RPAM
291
Rhenman & Partners Asset Management
Sweden
$12.8M +$6.42M +100,000 +73%
HEIP
292
Hudson Edge Investment Partners
New Jersey
$12.3M +$13.9M +215,865 +1,756%
ZIG
293
Zurich Insurance Group
Switzerland
$12.3M -$5.32M -82,759 -27%
MSA
294
Mason Street Advisors
Wisconsin
$12.2M +$76.2K +1,187 +0.5%
EDRH
295
Edmond de Rothschild Holding
Switzerland
$11.8M +$1.07M +16,670 +8%
ACM
296
Azimuth Capital Management
Michigan
$11.8M +$274K +4,265 +2%
EDRAMF
297
Edmond de Rothschild Asset Management (France)
France
$11.6M +$964K +15,000 +8%
PGFC
298
Peapack-Gladstone Financial Corp
New Jersey
$11.5M +$2.91M +45,316 +27%
GCP
299
GSA Capital Partners
United Kingdom
$11.3M +$11.9M +185,773 +775%
RI
300
RTW Investments
New York
$11.3M

BMY Hedge Fund Activity: Q3 2016 in Review

1,523 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb (BMY) for Q3 2016, worth a combined $63.3B — down 30% from $90.9B a quarter earlier.

Sellers outnumbered buyers: 147 funds closed out of BMY and 110 opened new positions — a net loss of 37 holders — while 548 trimmed existing stakes and 663 added.

The largest buyer was Wellington Management Group, adding an estimated $437M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.74B.

  • 1,523 institutional investors held Bristol-Myers Squibb (BMY) as of Q3 2016, down from 1,577 in Q2 2016.
  • Funds reported $63.3B of Bristol-Myers Squibb stock for Q3 2016, down 30% quarter-over-quarter.
  • 110 funds opened new Bristol-Myers Squibb positions in Q3 2016 and 147 closed out, a net change of -37 holders.
  • The largest Bristol-Myers Squibb buyer in Q3 2016 was Wellington Management Group, an estimated $437M added.
  • The largest Bristol-Myers Squibb seller in Q3 2016 was T. Rowe Price Associates, an estimated $1.74B sold.

Based on aggregated 13F filings for Q3 2016.